Back to Journals » OncoTargets and Therapy » Volume 12

Effects of BCc1 nanoparticle and its mixture with doxorubicin on survival of murine 4T1 tumor model

Authors Hafizi M, Soleimani M, Noorian S, Kalanaky S, Fakharzadeh S, Tavakolpoor Saleh N, Nazaran MH, Akbari ME

Received 4 January 2019

Accepted for publication 1 May 2019

Published 18 June 2019 Volume 2019:12 Pages 4691—4701


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati

Maryam Hafizi,1,2 Masoud Soleimani,3 Sajad Noorian,4 Somayeh Kalanaky,2 Saideh Fakharzadeh,2 Nafiseh Tavakolpoor Saleh,5 Mohammad Hassan Nazaran,2,* Mohammad Esmaeil Akbari,1,*

1Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; 3Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; 4Department of Statistics, Faculty of Sciences, University of Qom, Qom, Iran; 5Stem Cell Technology Research Center, Tehran, Iran

*These authors contributed equally to this work.

Background: Our previous findings showed that BCc1, a nanoparticle designed based on nanochelating technology, can be considered a new anti-cancer nanoparticle if confirmed by complementary studies.
Goal: In the present study, we investigated the effects of the BCc1 nanoparticle alone on some gene expressions influencing the apoptosis pathway, and also the effect of the mixture of BCc1 nanoparticle and doxorubicin on survival.
Method: Using an in vitro study, the effects of the BCc1 nanoparticle on Bax, Bcl2, p53, Caspase7 and p21 gene expressions were assessed after a 24-h treatment using real-time PCR in MCF-7 and MEFs; in addition, using an in vivo study, 4T1 tumor-bearing female Balb/c mice were treated with different doses of the BCc1 nanoparticle and doxorubicin alone and together and then their mean and median survival was evaluated.
Result: The results showed that the BCc1 nanoparticle increased gene expressions of RB, p53, Caspase7, p21, and Bax and decreased gene expressions of Bcl2 in MCF-7 significantly, but no change was observed in MEFs expressions. The findings revealed that the BCc1 nanoparticle, when used orally, had the highest mean and median survival time. A mixture of a high dose of the BCc1 nanoparticle (1 mg/kg) and a low dose of doxorubicin (0.1 mg/kg) showed synergistic effects on enhanced life span, while doxorubicin dose was prescribed approximately 50 times less than the murine applicable dose (5 mg/kg).
Conclusion: Our results demonstrated that the BCc1 nanoparticle not only has the potential to become a novel nanomedicine for cancer therapy, but it can also provide the basis of a new medicine for cancer management when mixed with a lower applicable dose of doxorubicin.

Keywords: BCc1 nanoparticle, cancer, doxorubicin, nanochelating technology, murine 4T1 tumor model

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]